Depletes Folic Acid. This medication is commonly used for Weight Loss
GLP 1 receptor agonists, used for both diabetes and weight management, can indirectly increase the risk of folate deficiency because they reduce overall food intake in a population that already tends to have low folate intake. Studies with potent incretin agonists show that when these drugs markedly suppress appetite and drive weight loss, blood folate levels can drop and then improve again when intake is restored, supporting a link between reduced intake and folate deficiency. In practice, this has prompted experts to emphasize monitoring folate status and diet quality in GLP 1 users, and many now recommend ensuring folate needs are met, often with folate or B complex supplement, for patients with low intake or anemia risk.
Guérard M, Zeller A, Festag M, Schubert C, Singer T, Müller L. Genotoxicity testing of peptides: folate deprivation as a marker of exaggerated pharmacology. Toxicol Appl Pharmacol. 2014 Sep 15;279(3):419-427. Kerlikowsky F, Krämer K, Eggersdorfer M, Hahn A. GLP-1 Receptor Agonists - Good for Body Weight, Bad for Micronutrient Status? Curr Dev Nutr. 2025 Oct 30;9(11):107587.Moyad MA. Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.). Curr Urol Rep. 2023 Nov;24(11):515-525. Kanai R, et al. Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes. Obes Pillars. 2024 Jan 3;9:100098. Sibal R, Balamurugan G, Langley J, Graham Y, Mahawar K. Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery? Nutrients. 2025 Nov 23;17(23):3659.
Folate (.2mg as L-5-Methylfolate) — 0.34 DFE
Low folate status contributes to elevated homocysteine, a metabolite that has been associated with endothelial dysfunction, arterial stiffness, and a higher risk of stroke and coronary heart disease. Large observational studies consistently show that individuals with higher homocysteine levels have greater rates of cardiovascular events, and folate intake is one of the key nutritional determinants of homocysteine. Clinically, folic acid supplementation (often combined with vitamins B6 and B12) can lower homocysteine and appears to modestly reduce stroke risk in some populations, making the identification and correction of folate deficiency an important part of broader cardiovascular risk reduction.
Folate deficiency in the periconceptional period significantly increases the risk of neural tube defects (NTDs) such as spina bifida and anencephaly, because adequate folate is required for proper closure of the embryonic neural tube in the first month of pregnancy. Large observational datasets and randomized trials have shown that appropriate folic acid supplementation before conception and in early pregnancy can reduce NTD risk by roughly 50–70% in the general population, with even greater risk reduction in women with a prior NTD‑affected pregnancy. The practical implication is that all women of childbearing potential, not just those actively planning pregnancy, are typically advised to maintain adequate daily folic acid intake so that red‑cell folate stores are sufficient well before conception occurs.
Prolonged use of Byetta can leave gaps in your nutrition. A targeted supplement can help restore balance while you continue treatment.

A bespoke formula designed to replenish the nutrients depleted by Byetta.
Once Daily Capsule · Rx Not Required
Learn More